evolent health inc. - EVH

EVH

Close Chg Chg %
8.20 0.16 1.89%

Closed Market

8.35

+0.16 (1.89%)

Volume: 1.40M

Last Updated:

Jun 6, 2025, 3:59 PM EDT

Company Overview: evolent health inc. - EVH

EVH Key Data

Open

$8.34

Day Range

8.18 - 8.51

52 Week Range

7.06 - 33.49

Market Cap

$961.51M

Shares Outstanding

117.40M

Public Float

114.47M

Beta

0.87

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.22

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.27M

 

EVH Performance

1 Week
 
11.81%
 
1 Month
 
-7.96%
 
3 Months
 
-7.34%
 
1 Year
 
-64.52%
 
5 Years
 
34.57%
 

EVH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About evolent health inc. - EVH

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

EVH At a Glance

Evolent Health, Inc.
1812 North Moore Street
Arlington, Virginia 22209
Phone 1-571-389-6000 Revenue 2.55B
Industry Miscellaneous Commercial Services Net Income -61,623,000.00
Sector Commercial Services 2024 Sales Growth 30.085%
Fiscal Year-end 12 / 2025 Employees 4,500
View SEC Filings

EVH Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.505
Price to Book Ratio 1.293
Price to Cash Flow Ratio 68.754
Enterprise Value to EBITDA 16.179
Enterprise Value to Sales 0.795
Total Debt to Enterprise Value 0.445

EVH Efficiency

Revenue/Employee 567,720.222
Income Per Employee -13,694.00
Receivables Turnover 6.161
Total Asset Turnover 0.978

EVH Liquidity

Current Ratio 0.849
Quick Ratio 0.849
Cash Ratio 0.229

EVH Profitability

Gross Margin 9.703
Operating Margin 0.091
Pretax Margin -2.467
Net Margin -2.412
Return on Assets -2.359
Return on Equity -5.957
Return on Total Capital -3.235
Return on Invested Capital -3.435

EVH Capital Structure

Total Debt to Total Equity 90.271
Total Debt to Total Capital 47.443
Total Debt to Total Assets 35.523
Long-Term Debt to Equity 70.477
Long-Term Debt to Total Capital 37.041
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Evolent Health Inc. - EVH

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
907.96M 1.35B 1.96B 2.55B
Sales Growth
-11.20% +48.91% +45.26% +30.09%
Cost of Goods Sold (COGS) incl D&A
717.59M 1.11B 1.63B 2.31B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
60.04M 90.25M 123.42M 123.17M
Depreciation
30.60M 32.00M 32.40M 30.30M
Amortization of Intangibles
29.44M 35.20M 91.02M 88.07M
COGS Growth
-15.85% +54.08% +47.14% +41.80%
Gross Income
190.37M 246.39M 337.06M 247.88M
Gross Income Growth
+12.16% +29.43% +36.80% -26.46%
Gross Profit Margin
+20.97% +18.22% +17.16% +9.70%
2021 2022 2023 2024 5-year trend
SG&A Expense
207.79M 241.33M 306.27M 245.55M
Research & Development
- - - 15.50M
-
Other SG&A
192.29M 241.33M 306.27M 245.55M
SGA Growth
-0.26% +16.14% +26.91% -19.83%
Other Operating Expense
- - - -
-
Unusual Expense
46.33M 57.56M 176.88M 42.99M
EBIT after Unusual Expense
(63.75M) (52.50M) (146.10M) (40.66M)
Non Operating Income/Expense
59.38M 6.00M (2.10M) 2.34M
Non-Operating Interest Income
407.00K 1.37M 5.26M 5.54M
Equity in Earnings of Affiliates
13.18M 4.57M 1.29M (3.44M)
Interest Expense
25.43M 15.57M 54.20M 24.72M
Interest Expense Growth
-10.28% -38.75% +248.09% -54.39%
Gross Interest Expense
25.43M 15.57M 54.20M 24.72M
Interest Capitalized
- - - -
-
Pretax Income
(29.80M) (62.08M) (202.41M) (63.04M)
Pretax Income Growth
+91.18% -108.31% -226.05% +68.86%
Pretax Margin
-3.28% -4.59% -10.31% -2.47%
Income Tax
483.00K (43.38M) (89.36M) (1.41M)
Income Tax - Current - Domestic
9.84M (47.05M) (35.93M) 15.96M
Income Tax - Current - Foreign
1.03M 1.32M 1.03M 1.45M
Income Tax - Deferred - Domestic
(9.89M) 2.27M (54.98M) (18.78M)
Income Tax - Deferred - Foreign
(493.00K) 92.00K 510.00K (49.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
13.18M 4.57M 1.29M (3.44M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(30.28M) (18.70M) (113.04M) (61.62M)
Minority Interest Expense
- - - -
-
Net Income
(30.28M) (18.70M) (113.04M) (61.62M)
Net Income Growth
+90.94% +38.25% -504.46% +45.49%
Net Margin Growth
-3.34% -1.38% -5.76% -2.41%
Extraordinaries & Discontinued Operations
- - (517.00K) 37.00K
-
Discontinued Operations
- - (517.00K) 37.00K
-
Net Income After Extraordinaries
(30.80M) (18.66M) (113.04M) (61.62M)
Preferred Dividends
- - 29.22M 31.83M
-
Net Income Available to Common
(30.80M) (18.66M) (142.26M) (93.45M)
EPS (Basic)
-0.3579 -0.1992 -1.2787 -0.8149
EPS (Basic) Growth
+90.91% +44.34% -541.92% +36.27%
Basic Shares Outstanding
86.07M 93.70M 111.25M 114.68M
EPS (Diluted)
-0.3579 -0.1992 -1.2787 -0.8149
EPS (Diluted) Growth
+90.91% +44.34% -541.92% +36.27%
Diluted Shares Outstanding
86.07M 93.70M 111.25M 114.68M
EBITDA
42.62M 95.31M 154.20M 125.50M
EBITDA Growth
-3.32% +123.64% +61.79% -18.61%
EBITDA Margin
+4.69% +7.05% +7.85% +4.91%

Snapshot

Average Recommendation BUY Average Target Price 15.308
Number of Ratings 14 Current Quarters Estimate 0.078
FY Report Date 06 / 2025 Current Year's Estimate 0.351
Last Quarter’s Earnings 0.06 Median PE on CY Estimate N/A
Year Ago Earnings 0.41 Next Fiscal Year Estimate 0.589
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 11 11
Mean Estimate 0.08 0.10 0.35 0.59
High Estimates 0.16 0.18 0.59 0.89
Low Estimate -0.01 0.04 0.10 0.38
Coefficient of Variance 65.54 50.09 42.81 25.85

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 13
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Evolent Health Inc. - EVH

Date Name Shares Transaction Value
Mar 6, 2025 Brendan B. Springstubb Director 6,842 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Brendan B. Springstubb Director 11,842 Open market or private purchase of non-derivative security Non-derivative transaction at $8.75 per share 103,617.50
Jun 11, 2024 Peter Grua Director 12,758 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Richard M. Jelinek Director 14,458 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Cheryl M. Scott Director 51,497 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Russell M. Glass Director 8,872 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Mary Bridget Duffy Director 48,001 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Kim A. Keck Director 28,982 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Craig A. Barbarosh Director 29,956 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Diane P. Holder Director 67,849 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Toyin Ajayi Director 12,095 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Evolent Health Inc. in the News